nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—PTGS2—colon cancer	0.658	1	CbGaD
Clodronate—Hepatic cancer metastatic—Irinotecan—colon cancer	0.0188	0.124	CcSEcCtD
Clodronate—Metastases to liver—Irinotecan—colon cancer	0.0188	0.124	CcSEcCtD
Clodronate—SLC25A6—Influenza Virus Induced Apoptosis—TGFB1—colon cancer	0.0133	0.256	CbGpPWpGaD
Clodronate—Hepatic cancer metastatic—Capecitabine—colon cancer	0.0126	0.0831	CcSEcCtD
Clodronate—Metastases to liver—Capecitabine—colon cancer	0.0126	0.0831	CcSEcCtD
Clodronate—SLC25A6—embryo—colon cancer	0.00869	0.0665	CbGeAlD
Clodronate—SLC25A5—embryo—colon cancer	0.00756	0.0578	CbGeAlD
Clodronate—SLC25A6—Vinorelbine—Vincristine—colon cancer	0.00732	1	CbGdCrCtD
Clodronate—SLC25A6—epithelium—colon cancer	0.00709	0.0542	CbGeAlD
Clodronate—SLC25A6—renal system—colon cancer	0.00657	0.0503	CbGeAlD
Clodronate—SLC25A6—Host Interactions with Influenza Factors—TGFB1—colon cancer	0.00641	0.123	CbGpPWpGaD
Clodronate—SLC25A5—epithelium—colon cancer	0.00617	0.0472	CbGeAlD
Clodronate—SLC25A5—smooth muscle tissue—colon cancer	0.00594	0.0455	CbGeAlD
Clodronate—SLC25A5—renal system—colon cancer	0.00572	0.0438	CbGeAlD
Clodronate—Acute leukaemia—Irinotecan—colon cancer	0.00548	0.0362	CcSEcCtD
Clodronate—SLC25A6—lymphoid tissue—colon cancer	0.00546	0.0418	CbGeAlD
Clodronate—SLC25A6—digestive system—colon cancer	0.00539	0.0413	CbGeAlD
Clodronate—SLC25A4—renal system—colon cancer	0.00536	0.041	CbGeAlD
Clodronate—SLC25A6—bone marrow—colon cancer	0.00497	0.038	CbGeAlD
Clodronate—SLC25A5—lymphoid tissue—colon cancer	0.00475	0.0363	CbGeAlD
Clodronate—SLC25A5—digestive system—colon cancer	0.00469	0.0359	CbGeAlD
Clodronate—SLC25A4—digestive system—colon cancer	0.0044	0.0336	CbGeAlD
Clodronate—SLC25A5—bone marrow—colon cancer	0.00432	0.0331	CbGeAlD
Clodronate—SLC25A5—vagina—colon cancer	0.00414	0.0317	CbGeAlD
Clodronate—SLC25A6—liver—colon cancer	0.00402	0.0307	CbGeAlD
Clodronate—SLC25A4—vagina—colon cancer	0.00388	0.0297	CbGeAlD
Clodronate—SLC25A5—liver—colon cancer	0.0035	0.0267	CbGeAlD
Clodronate—SLC25A4—liver—colon cancer	0.00328	0.0251	CbGeAlD
Clodronate—SLC25A6—lymph node—colon cancer	0.00308	0.0236	CbGeAlD
Clodronate—Local reaction—Fluorouracil—colon cancer	0.00271	0.0179	CcSEcCtD
Clodronate—SLC25A5—lymph node—colon cancer	0.00268	0.0205	CbGeAlD
Clodronate—PTGS2—endothelium—colon cancer	0.00259	0.0198	CbGeAlD
Clodronate—Gastrointestinal symptom NOS—Fluorouracil—colon cancer	0.00255	0.0169	CcSEcCtD
Clodronate—Serum creatinine increased—Irinotecan—colon cancer	0.00255	0.0168	CcSEcCtD
Clodronate—SLC25A4—lymph node—colon cancer	0.00251	0.0192	CbGeAlD
Clodronate—PTGS2—blood vessel—colon cancer	0.00239	0.0183	CbGeAlD
Clodronate—PTGS2—gall bladder—colon cancer	0.00224	0.0172	CbGeAlD
Clodronate—Extravasation—Vincristine—colon cancer	0.00184	0.0122	CcSEcCtD
Clodronate—Neoplasm malignant—Irinotecan—colon cancer	0.00184	0.0121	CcSEcCtD
Clodronate—Extravasation—Irinotecan—colon cancer	0.0018	0.0119	CcSEcCtD
Clodronate—Extravasation—Fluorouracil—colon cancer	0.00172	0.0114	CcSEcCtD
Clodronate—Serum creatinine increased—Capecitabine—colon cancer	0.0017	0.0113	CcSEcCtD
Clodronate—Hypercalcaemia—Capecitabine—colon cancer	0.00151	0.00997	CcSEcCtD
Clodronate—PTGS2—embryo—colon cancer	0.00142	0.0109	CbGeAlD
Clodronate—Renal failure acute—Irinotecan—colon cancer	0.00123	0.00814	CcSEcCtD
Clodronate—SLC25A5—Metabolism—CA7—colon cancer	0.00122	0.0234	CbGpPWpGaD
Clodronate—Renal impairment—Irinotecan—colon cancer	0.0012	0.00789	CcSEcCtD
Clodronate—Proteinuria—Capecitabine—colon cancer	0.00119	0.00788	CcSEcCtD
Clodronate—Protein urine present—Capecitabine—colon cancer	0.00118	0.00777	CcSEcCtD
Clodronate—PTGS2—epithelium—colon cancer	0.00116	0.00888	CbGeAlD
Clodronate—Hypocalcaemia—Capecitabine—colon cancer	0.00115	0.00757	CcSEcCtD
Clodronate—Liver disorder—Methotrexate—colon cancer	0.00115	0.00756	CcSEcCtD
Clodronate—PTGS2—smooth muscle tissue—colon cancer	0.00112	0.00856	CbGeAlD
Clodronate—Cardiac failure—Fluorouracil—colon cancer	0.00112	0.00737	CcSEcCtD
Clodronate—Dehydration—Vincristine—colon cancer	0.00109	0.00717	CcSEcCtD
Clodronate—PTGS2—renal system—colon cancer	0.00108	0.00824	CbGeAlD
Clodronate—Blood creatinine increased—Irinotecan—colon cancer	0.00107	0.00704	CcSEcCtD
Clodronate—Dehydration—Irinotecan—colon cancer	0.00106	0.00699	CcSEcCtD
Clodronate—SLC25A6—Metabolism—CA7—colon cancer	0.00102	0.0196	CbGpPWpGaD
Clodronate—Dysphagia—Fluorouracil—colon cancer	0.000942	0.00622	CcSEcCtD
Clodronate—Pneumonia—Vincristine—colon cancer	0.000905	0.00598	CcSEcCtD
Clodronate—Extravasation—Methotrexate—colon cancer	0.000895	0.00591	CcSEcCtD
Clodronate—PTGS2—lymphoid tissue—colon cancer	0.000894	0.00684	CbGeAlD
Clodronate—Proteinuria—Methotrexate—colon cancer	0.000889	0.00587	CcSEcCtD
Clodronate—PTGS2—digestive system—colon cancer	0.000883	0.00676	CbGeAlD
Clodronate—SLC25A5—Disease—CHST5—colon cancer	0.000882	0.0169	CbGpPWpGaD
Clodronate—SLC25A5—Disease—LGR5—colon cancer	0.000882	0.0169	CbGpPWpGaD
Clodronate—Pneumonia—Irinotecan—colon cancer	0.000882	0.00582	CcSEcCtD
Clodronate—Protein urine present—Methotrexate—colon cancer	0.000876	0.00579	CcSEcCtD
Clodronate—Hepatic function abnormal—Capecitabine—colon cancer	0.000871	0.00575	CcSEcCtD
Clodronate—Renal failure—Irinotecan—colon cancer	0.000862	0.00569	CcSEcCtD
Clodronate—Oliguria—Methotrexate—colon cancer	0.000847	0.0056	CcSEcCtD
Clodronate—Pneumonia—Fluorouracil—colon cancer	0.000844	0.00558	CcSEcCtD
Clodronate—Renal failure acute—Capecitabine—colon cancer	0.000825	0.00545	CcSEcCtD
Clodronate—PTGS2—bone marrow—colon cancer	0.000814	0.00623	CbGeAlD
Clodronate—PTGS2—Overview of nanoparticle effects—BAX—colon cancer	0.000813	0.0156	CbGpPWpGaD
Clodronate—Renal impairment—Capecitabine—colon cancer	0.0008	0.00528	CcSEcCtD
Clodronate—Urinary tract disorder—Vincristine—colon cancer	0.000798	0.00527	CcSEcCtD
Clodronate—SLC25A4—Metabolism—CA7—colon cancer	0.000797	0.0153	CbGpPWpGaD
Clodronate—Connective tissue disorder—Vincristine—colon cancer	0.000794	0.00524	CcSEcCtD
Clodronate—Urethral disorder—Vincristine—colon cancer	0.000792	0.00523	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—CDX2—colon cancer	0.000789	0.0151	CbGpPWpGaD
Clodronate—PTGS2—vagina—colon cancer	0.00078	0.00597	CbGeAlD
Clodronate—Cardiac failure—Capecitabine—colon cancer	0.00078	0.00515	CcSEcCtD
Clodronate—Connective tissue disorder—Irinotecan—colon cancer	0.000773	0.00511	CcSEcCtD
Clodronate—Pharyngitis—Fluorouracil—colon cancer	0.000748	0.00494	CcSEcCtD
Clodronate—SLC25A6—Disease—CHST5—colon cancer	0.000739	0.0142	CbGpPWpGaD
Clodronate—SLC25A6—Disease—LGR5—colon cancer	0.000739	0.0142	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—CHST5—colon cancer	0.000738	0.0142	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—ODC1—colon cancer	0.000738	0.0142	CbGpPWpGaD
Clodronate—Mediastinal disorder—Vincristine—colon cancer	0.000728	0.00481	CcSEcCtD
Clodronate—Blood creatinine increased—Capecitabine—colon cancer	0.000713	0.00471	CcSEcCtD
Clodronate—Mediastinal disorder—Irinotecan—colon cancer	0.000709	0.00468	CcSEcCtD
Clodronate—Dehydration—Capecitabine—colon cancer	0.000708	0.00468	CcSEcCtD
Clodronate—Abdominal pain upper—Capecitabine—colon cancer	0.000695	0.00459	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Capecitabine—colon cancer	0.000671	0.00443	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—MUC2—colon cancer	0.000671	0.0129	CbGpPWpGaD
Clodronate—PTGS2—liver—colon cancer	0.000658	0.00504	CbGeAlD
Clodronate—Dysphagia—Capecitabine—colon cancer	0.000658	0.00435	CcSEcCtD
Clodronate—Anaemia—Vincristine—colon cancer	0.00065	0.00429	CcSEcCtD
Clodronate—Bronchospasm—Capecitabine—colon cancer	0.000647	0.00427	CcSEcCtD
Clodronate—SLC25A5—Disease—AXIN2—colon cancer	0.000633	0.0121	CbGpPWpGaD
Clodronate—Anaemia—Irinotecan—colon cancer	0.000633	0.00418	CcSEcCtD
Clodronate—SLC25A6—Metabolism—ODC1—colon cancer	0.000619	0.0119	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—CHST5—colon cancer	0.000619	0.0119	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—CDX2—colon cancer	0.000616	0.0118	CbGpPWpGaD
Clodronate—Renal failure acute—Methotrexate—colon cancer	0.000614	0.00405	CcSEcCtD
Clodronate—Anaemia—Fluorouracil—colon cancer	0.000606	0.004	CcSEcCtD
Clodronate—Pneumonia—Capecitabine—colon cancer	0.00059	0.0039	CcSEcCtD
Clodronate—SLC25A4—Disease—CHST5—colon cancer	0.000577	0.0111	CbGpPWpGaD
Clodronate—SLC25A4—Disease—LGR5—colon cancer	0.000577	0.0111	CbGpPWpGaD
Clodronate—Renal failure—Capecitabine—colon cancer	0.000577	0.00381	CcSEcCtD
Clodronate—Infection—Vincristine—colon cancer	0.00057	0.00377	CcSEcCtD
Clodronate—Infection—Irinotecan—colon cancer	0.000555	0.00367	CcSEcCtD
Clodronate—Anorexia—Vincristine—colon cancer	0.000547	0.00361	CcSEcCtD
Clodronate—Anorexia—Irinotecan—colon cancer	0.000533	0.00352	CcSEcCtD
Clodronate—Infection—Fluorouracil—colon cancer	0.000532	0.00351	CcSEcCtD
Clodronate—SLC25A6—Disease—AXIN2—colon cancer	0.000531	0.0102	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—MUC2—colon cancer	0.000524	0.01	CbGpPWpGaD
Clodronate—Pharyngitis—Capecitabine—colon cancer	0.000523	0.00345	CcSEcCtD
Clodronate—Urinary tract disorder—Capecitabine—colon cancer	0.00052	0.00344	CcSEcCtD
Clodronate—Connective tissue disorder—Capecitabine—colon cancer	0.000518	0.00342	CcSEcCtD
Clodronate—Urethral disorder—Capecitabine—colon cancer	0.000516	0.00341	CcSEcCtD
Clodronate—Anorexia—Fluorouracil—colon cancer	0.00051	0.00337	CcSEcCtD
Clodronate—PTGS2—lymph node—colon cancer	0.000505	0.00386	CbGeAlD
Clodronate—Decreased appetite—Vincristine—colon cancer	0.000499	0.0033	CcSEcCtD
Clodronate—Dyspnoea—Irinotecan—colon cancer	0.000498	0.00329	CcSEcCtD
Clodronate—Gastrointestinal disorder—Vincristine—colon cancer	0.000496	0.00327	CcSEcCtD
Clodronate—Dyspepsia—Irinotecan—colon cancer	0.000492	0.00325	CcSEcCtD
Clodronate—Decreased appetite—Irinotecan—colon cancer	0.000486	0.00321	CcSEcCtD
Clodronate—SLC25A4—Metabolism—ODC1—colon cancer	0.000483	0.00926	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—CHST5—colon cancer	0.000483	0.00926	CbGpPWpGaD
Clodronate—Gastrointestinal disorder—Irinotecan—colon cancer	0.000483	0.00319	CcSEcCtD
Clodronate—Dyspnoea—Fluorouracil—colon cancer	0.000477	0.00315	CcSEcCtD
Clodronate—Mediastinal disorder—Capecitabine—colon cancer	0.000475	0.00313	CcSEcCtD
Clodronate—Dyspepsia—Fluorouracil—colon cancer	0.000471	0.00311	CcSEcCtD
Clodronate—Decreased appetite—Fluorouracil—colon cancer	0.000465	0.00307	CcSEcCtD
Clodronate—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000462	0.00305	CcSEcCtD
Clodronate—Abdominal pain—Vincristine—colon cancer	0.000454	0.003	CcSEcCtD
Clodronate—SLC25A6—Influenza Infection—TGFB1—colon cancer	0.000444	0.0085	CbGpPWpGaD
Clodronate—Abdominal pain—Irinotecan—colon cancer	0.000442	0.00292	CcSEcCtD
Clodronate—Pneumonia—Methotrexate—colon cancer	0.000439	0.0029	CcSEcCtD
Clodronate—Renal failure—Methotrexate—colon cancer	0.000429	0.00284	CcSEcCtD
Clodronate—Urticaria—Fluorouracil—colon cancer	0.000425	0.00281	CcSEcCtD
Clodronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—colon cancer	0.000425	0.00815	CbGpPWpGaD
Clodronate—Anaemia—Capecitabine—colon cancer	0.000424	0.0028	CcSEcCtD
Clodronate—SLC25A4—Disease—AXIN2—colon cancer	0.000414	0.00794	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—CASP3—colon cancer	0.00041	0.00786	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—CTNNB1—colon cancer	0.000395	0.00757	CbGpPWpGaD
Clodronate—Diarrhoea—Vincristine—colon cancer	0.000393	0.00259	CcSEcCtD
Clodronate—Pharyngitis—Methotrexate—colon cancer	0.000389	0.00257	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000388	0.00256	CcSEcCtD
Clodronate—Urinary tract disorder—Methotrexate—colon cancer	0.000387	0.00256	CcSEcCtD
Clodronate—Urethral disorder—Methotrexate—colon cancer	0.000384	0.00254	CcSEcCtD
Clodronate—Diarrhoea—Irinotecan—colon cancer	0.000382	0.00253	CcSEcCtD
Clodronate—Pruritus—Fluorouracil—colon cancer	0.000379	0.0025	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.000379	0.00726	CbGpPWpGaD
Clodronate—Infection—Capecitabine—colon cancer	0.000372	0.00246	CcSEcCtD
Clodronate—PTGS2—S1P1 pathway—VEGFA—colon cancer	0.000371	0.0071	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—EP300—colon cancer	0.000367	0.00704	CbGpPWpGaD
Clodronate—Diarrhoea—Fluorouracil—colon cancer	0.000366	0.00242	CcSEcCtD
Clodronate—Vomiting—Vincristine—colon cancer	0.000365	0.00241	CcSEcCtD
Clodronate—Skin disorder—Capecitabine—colon cancer	0.000363	0.0024	CcSEcCtD
Clodronate—Rash—Vincristine—colon cancer	0.000362	0.00239	CcSEcCtD
Clodronate—Dermatitis—Vincristine—colon cancer	0.000362	0.00239	CcSEcCtD
Clodronate—Anorexia—Capecitabine—colon cancer	0.000357	0.00236	CcSEcCtD
Clodronate—Vomiting—Irinotecan—colon cancer	0.000355	0.00235	CcSEcCtD
Clodronate—Mediastinal disorder—Methotrexate—colon cancer	0.000353	0.00233	CcSEcCtD
Clodronate—Rash—Irinotecan—colon cancer	0.000352	0.00233	CcSEcCtD
Clodronate—Dermatitis—Irinotecan—colon cancer	0.000352	0.00233	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—VEGFA—colon cancer	0.000348	0.00667	CbGpPWpGaD
Clodronate—Nausea—Vincristine—colon cancer	0.000341	0.00225	CcSEcCtD
Clodronate—Vomiting—Fluorouracil—colon cancer	0.00034	0.00225	CcSEcCtD
Clodronate—Rash—Fluorouracil—colon cancer	0.000338	0.00223	CcSEcCtD
Clodronate—Dermatitis—Fluorouracil—colon cancer	0.000337	0.00223	CcSEcCtD
Clodronate—Dyspnoea—Capecitabine—colon cancer	0.000334	0.0022	CcSEcCtD
Clodronate—Nausea—Irinotecan—colon cancer	0.000332	0.00219	CcSEcCtD
Clodronate—Dyspepsia—Capecitabine—colon cancer	0.000329	0.00218	CcSEcCtD
Clodronate—Decreased appetite—Capecitabine—colon cancer	0.000325	0.00215	CcSEcCtD
Clodronate—Gastrointestinal disorder—Capecitabine—colon cancer	0.000323	0.00213	CcSEcCtD
Clodronate—Nausea—Fluorouracil—colon cancer	0.000318	0.0021	CcSEcCtD
Clodronate—Anaemia—Methotrexate—colon cancer	0.000315	0.00208	CcSEcCtD
Clodronate—Urticaria—Capecitabine—colon cancer	0.000297	0.00196	CcSEcCtD
Clodronate—Abdominal pain—Capecitabine—colon cancer	0.000296	0.00195	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000289	0.00191	CcSEcCtD
Clodronate—Infection—Methotrexate—colon cancer	0.000277	0.00183	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—colon cancer	0.000276	0.00529	CbGpPWpGaD
Clodronate—Skin disorder—Methotrexate—colon cancer	0.000271	0.00179	CcSEcCtD
Clodronate—Anorexia—Methotrexate—colon cancer	0.000265	0.00175	CcSEcCtD
Clodronate—Pruritus—Capecitabine—colon cancer	0.000265	0.00175	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.000258	0.00495	CbGpPWpGaD
Clodronate—Diarrhoea—Capecitabine—colon cancer	0.000256	0.00169	CcSEcCtD
Clodronate—Dyspnoea—Methotrexate—colon cancer	0.000248	0.00164	CcSEcCtD
Clodronate—Dyspepsia—Methotrexate—colon cancer	0.000245	0.00162	CcSEcCtD
Clodronate—Decreased appetite—Methotrexate—colon cancer	0.000242	0.0016	CcSEcCtD
Clodronate—Gastrointestinal disorder—Methotrexate—colon cancer	0.00024	0.00159	CcSEcCtD
Clodronate—Vomiting—Capecitabine—colon cancer	0.000238	0.00157	CcSEcCtD
Clodronate—Rash—Capecitabine—colon cancer	0.000236	0.00156	CcSEcCtD
Clodronate—Dermatitis—Capecitabine—colon cancer	0.000236	0.00156	CcSEcCtD
Clodronate—Nausea—Capecitabine—colon cancer	0.000222	0.00147	CcSEcCtD
Clodronate—Urticaria—Methotrexate—colon cancer	0.000221	0.00146	CcSEcCtD
Clodronate—Abdominal pain—Methotrexate—colon cancer	0.00022	0.00145	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.000217	0.00417	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	0.000203	0.00389	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—colon cancer	0.000201	0.00386	CbGpPWpGaD
Clodronate—Pruritus—Methotrexate—colon cancer	0.000197	0.0013	CcSEcCtD
Clodronate—SLC25A5—Metabolism—ABCB1—colon cancer	0.000195	0.00374	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—EP300—colon cancer	0.000193	0.0037	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—TYMS—colon cancer	0.000192	0.00367	CbGpPWpGaD
Clodronate—Diarrhoea—Methotrexate—colon cancer	0.000191	0.00126	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—SRC—colon cancer	0.000188	0.0036	CbGpPWpGaD
Clodronate—SLC25A5—Disease—FGFR3—colon cancer	0.000183	0.00351	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	0.000183	0.0035	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	0.00018	0.00346	CbGpPWpGaD
Clodronate—Vomiting—Methotrexate—colon cancer	0.000177	0.00117	CcSEcCtD
Clodronate—Rash—Methotrexate—colon cancer	0.000176	0.00116	CcSEcCtD
Clodronate—Dermatitis—Methotrexate—colon cancer	0.000175	0.00116	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000174	0.00333	CbGpPWpGaD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—colon cancer	0.000172	0.00329	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—MYC—colon cancer	0.000168	0.00322	CbGpPWpGaD
Clodronate—SLC25A5—Disease—APC—colon cancer	0.000168	0.00322	CbGpPWpGaD
Clodronate—Nausea—Methotrexate—colon cancer	0.000165	0.00109	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	0.000164	0.00315	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—ABCB1—colon cancer	0.000164	0.00313	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—TYMS—colon cancer	0.000161	0.00308	CbGpPWpGaD
Clodronate—SLC25A5—Disease—BRAF—colon cancer	0.000158	0.00303	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CA7—colon cancer	0.000158	0.00302	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—CTNNB1—colon cancer	0.000155	0.00298	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	0.000155	0.00298	CbGpPWpGaD
Clodronate—SLC25A6—Disease—FGFR3—colon cancer	0.000153	0.00294	CbGpPWpGaD
Clodronate—SLC25A6—Disease—APC—colon cancer	0.000141	0.0027	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PPARG—colon cancer	0.000136	0.0026	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000136	0.0026	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000133	0.00255	CbGpPWpGaD
Clodronate—SLC25A6—Disease—BRAF—colon cancer	0.000132	0.00254	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	0.000132	0.00253	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CCND1—colon cancer	0.000129	0.00248	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000128	0.00246	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—ABCB1—colon cancer	0.000128	0.00245	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PTGS2—colon cancer	0.000128	0.00244	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—TYMS—colon cancer	0.000125	0.0024	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CDKN1A—colon cancer	0.000125	0.0024	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—CTNNB1—colon cancer	0.000121	0.00232	CbGpPWpGaD
Clodronate—SLC25A4—Disease—FGFR3—colon cancer	0.00012	0.00229	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—EP300—colon cancer	0.000119	0.00228	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CTNNB1—colon cancer	0.000114	0.00219	CbGpPWpGaD
Clodronate—PTGS2—Disease—LGR5—colon cancer	0.000114	0.00219	CbGpPWpGaD
Clodronate—PTGS2—Disease—CHST5—colon cancer	0.000114	0.00219	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PPARG—colon cancer	0.000114	0.00218	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—NRAS—colon cancer	0.000111	0.00214	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CDKN1A—colon cancer	0.000111	0.00214	CbGpPWpGaD
Clodronate—SLC25A4—Disease—APC—colon cancer	0.00011	0.00211	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PTGS2—colon cancer	0.000107	0.00205	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PTGS2—colon cancer	0.000107	0.00205	CbGpPWpGaD
Clodronate—SLC25A5—Disease—EP300—colon cancer	0.000106	0.00203	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—MYC—colon cancer	0.000104	0.00199	CbGpPWpGaD
Clodronate—SLC25A4—Disease—BRAF—colon cancer	0.000103	0.00198	CbGpPWpGaD
Clodronate—SLC25A5—Disease—SRC—colon cancer	0.000103	0.00198	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CASP3—colon cancer	0.000101	0.00194	CbGpPWpGaD
Clodronate—SLC25A5—Disease—NRAS—colon cancer	9.92e-05	0.0019	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CCND1—colon cancer	9.86e-05	0.00189	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—APC—colon cancer	9.78e-05	0.00187	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—KRAS—colon cancer	9.6e-05	0.00184	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CTNNB1—colon cancer	9.56e-05	0.00183	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CHST5—colon cancer	9.55e-05	0.00183	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ODC1—colon cancer	9.55e-05	0.00183	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CDKN1A—colon cancer	9.34e-05	0.00179	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MYC—colon cancer	9.24e-05	0.00177	CbGpPWpGaD
Clodronate—SLC25A5—Disease—TGFB1—colon cancer	9.22e-05	0.00177	CbGpPWpGaD
Clodronate—SLC25A5—Disease—EGFR—colon cancer	9.04e-05	0.00173	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTGS2—colon cancer	8.95e-05	0.00172	CbGpPWpGaD
Clodronate—SLC25A6—Disease—EP300—colon cancer	8.89e-05	0.0017	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—EP300—colon cancer	8.88e-05	0.0017	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PPARG—colon cancer	8.88e-05	0.0017	CbGpPWpGaD
Clodronate—SLC25A6—Disease—SRC—colon cancer	8.64e-05	0.00166	CbGpPWpGaD
Clodronate—SLC25A5—Disease—KRAS—colon cancer	8.54e-05	0.00164	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PTGS2—colon cancer	8.34e-05	0.0016	CbGpPWpGaD
Clodronate—SLC25A6—Disease—NRAS—colon cancer	8.31e-05	0.00159	CbGpPWpGaD
Clodronate—PTGS2—Disease—AXIN2—colon cancer	8.19e-05	0.00157	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—HRAS—colon cancer	8.16e-05	0.00156	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MYC—colon cancer	7.91e-05	0.00152	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TGFB1—colon cancer	7.89e-05	0.00151	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PIK3CA—colon cancer	7.84e-05	0.0015	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MYC—colon cancer	7.74e-05	0.00148	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—EGFR—colon cancer	7.74e-05	0.00148	CbGpPWpGaD
Clodronate—SLC25A6—Disease—TGFB1—colon cancer	7.73e-05	0.00148	CbGpPWpGaD
Clodronate—SLC25A6—Disease—EGFR—colon cancer	7.57e-05	0.00145	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CTNNB1—colon cancer	7.46e-05	0.00143	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—EP300—colon cancer	7.44e-05	0.00143	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CDKN1A—colon cancer	7.29e-05	0.0014	CbGpPWpGaD
Clodronate—SLC25A5—Disease—HRAS—colon cancer	7.26e-05	0.00139	CbGpPWpGaD
Clodronate—SLC25A6—Disease—KRAS—colon cancer	7.16e-05	0.00137	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTGS2—colon cancer	6.99e-05	0.00134	CbGpPWpGaD
Clodronate—SLC25A4—Disease—EP300—colon cancer	6.94e-05	0.00133	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	6.89e-05	0.00132	CbGpPWpGaD
Clodronate—SLC25A4—Disease—SRC—colon cancer	6.75e-05	0.00129	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	6.71e-05	0.00129	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	6.65e-05	0.00127	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PIK3CA—colon cancer	6.57e-05	0.00126	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PIK3CA—colon cancer	6.57e-05	0.00126	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TP53—colon cancer	6.5e-05	0.00125	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	6.49e-05	0.00124	CbGpPWpGaD
Clodronate—SLC25A4—Disease—NRAS—colon cancer	6.49e-05	0.00124	CbGpPWpGaD
Clodronate—SLC25A5—Disease—AKT1—colon cancer	6.41e-05	0.00123	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	6.18e-05	0.00118	CbGpPWpGaD
Clodronate—SLC25A6—Disease—HRAS—colon cancer	6.08e-05	0.00117	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MYC—colon cancer	6.05e-05	0.00116	CbGpPWpGaD
Clodronate—SLC25A4—Disease—TGFB1—colon cancer	6.03e-05	0.00116	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	6.01e-05	0.00115	CbGpPWpGaD
Clodronate—SLC25A4—Disease—EGFR—colon cancer	5.91e-05	0.00113	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	5.85e-05	0.00112	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—EP300—colon cancer	5.81e-05	0.00111	CbGpPWpGaD
Clodronate—SLC25A4—Disease—KRAS—colon cancer	5.59e-05	0.00107	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PIK3CA—colon cancer	5.51e-05	0.00106	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	5.38e-05	0.00103	CbGpPWpGaD
Clodronate—SLC25A6—Disease—AKT1—colon cancer	5.37e-05	0.00103	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	5.37e-05	0.00103	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—AKT1—colon cancer	5.37e-05	0.00103	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	5.26e-05	0.00101	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PIK3CA—colon cancer	5.13e-05	0.000984	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	4.97e-05	0.000953	CbGpPWpGaD
Clodronate—SLC25A4—Disease—HRAS—colon cancer	4.75e-05	0.00091	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	4.57e-05	0.000876	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—AKT1—colon cancer	4.5e-05	0.000862	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	4.42e-05	0.000847	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PIK3CA—colon cancer	4.3e-05	0.000824	CbGpPWpGaD
Clodronate—SLC25A4—Disease—AKT1—colon cancer	4.19e-05	0.000804	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.94e-05	0.000756	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	3.73e-05	0.000715	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—AKT1—colon cancer	3.51e-05	0.000673	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.58e-05	0.000494	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ABCB1—colon cancer	2.52e-05	0.000484	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—TYMS—colon cancer	2.48e-05	0.000475	CbGpPWpGaD
Clodronate—PTGS2—Disease—FGFR3—colon cancer	2.37e-05	0.000453	CbGpPWpGaD
Clodronate—PTGS2—Disease—APC—colon cancer	2.17e-05	0.000416	CbGpPWpGaD
Clodronate—PTGS2—Disease—BRAF—colon cancer	2.04e-05	0.000391	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.91e-05	0.000366	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PPARG—colon cancer	1.76e-05	0.000336	CbGpPWpGaD
Clodronate—PTGS2—Disease—CTNNB1—colon cancer	1.48e-05	0.000283	CbGpPWpGaD
Clodronate—PTGS2—Disease—CDKN1A—colon cancer	1.44e-05	0.000276	CbGpPWpGaD
Clodronate—PTGS2—Disease—EP300—colon cancer	1.37e-05	0.000263	CbGpPWpGaD
Clodronate—PTGS2—Disease—SRC—colon cancer	1.33e-05	0.000256	CbGpPWpGaD
Clodronate—PTGS2—Disease—NRAS—colon cancer	1.28e-05	0.000246	CbGpPWpGaD
Clodronate—PTGS2—Disease—MYC—colon cancer	1.2e-05	0.000229	CbGpPWpGaD
Clodronate—PTGS2—Disease—TGFB1—colon cancer	1.19e-05	0.000229	CbGpPWpGaD
Clodronate—PTGS2—Disease—EGFR—colon cancer	1.17e-05	0.000224	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—EP300—colon cancer	1.15e-05	0.00022	CbGpPWpGaD
Clodronate—PTGS2—Disease—KRAS—colon cancer	1.1e-05	0.000212	CbGpPWpGaD
Clodronate—PTGS2—Disease—PIK3CA—colon cancer	1.01e-05	0.000194	CbGpPWpGaD
Clodronate—PTGS2—Disease—HRAS—colon cancer	9.39e-06	0.00018	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CA—colon cancer	8.5e-06	0.000163	CbGpPWpGaD
Clodronate—PTGS2—Disease—AKT1—colon cancer	8.29e-06	0.000159	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—AKT1—colon cancer	6.94e-06	0.000133	CbGpPWpGaD
